Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital, Oncode Oncology Bridge Fund, Swanbridge, Innovatiefonds Noord Holland, and BOM. Flindr has entered into a research collaboration with the NKI, and the VIB (Flanders Institute of Biotechnology). 



Biotechnology

Life Sciences

Research

Therapeutics

Flindr Therapeutics

Flindr Therapeutics' headquarters in Oss, Netherlands

Maarten Ligtenberg

Sally Ross

Joëlle Vos

Jac Wijkmans

This department provides strategic direction and governance for the organization.

Executive Leadership

This department focuses on conducting research and developing innovative solutions to advance scientific knowledge and applications.

Flindr Therapeutics

Org chart

Teams

Executive Leadership

Research and Development

Offices

Flindr Therapeutics

Org chart

Teams

Executive Leadership

Research and Development

Offices

Related companies